BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

BioAge Labs, Inc.NASDAQ: BIOA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $63K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $63K.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $63K or moves back toward the trailing-twelve-month quarterly average of $15.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$63K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$63K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 0.6% of revenue for BIOA, versus a peer median of 72.0%.
BIOA Competitors
Cost of Revenue for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$234.68M CAD+23.9%-0.9%75.1%
ACBAurora Cannabis Inc.LTM Mar 2026CA$134.79M CAD-13.4%+13.4%43.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$93.03M USD—+7.0%68.8%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M USD-23.8%-4.7%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$40.76M USD+72.9%——
EDITEditas Medicine, Inc.LTM Mar 2026$36.44M USD-53.4%—94.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$27.87M USD-7.8%+4.2%66.7%
HUMAHumacyte, Inc.LTM Mar 2026$17.11M USD+85.4%+27.3%848.5%
BIOABioAge Labs, Inc.LTM Mar 2026$63K USD——0.6%
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding BIOA) —-7.8%+5.6%72.0%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.